In 2015, more than of 125,000 transplantations were performed worldwide, an increase of over 5.5% from 2014, with around 33,000 of these occurring in the EU and a further 32,000 in the US. Approximately 60% of these were kidney transplants, with liver, heart, lung, pancreas and small bowel transplantations accounting for the other most common procedures.

Generally, there are a modest number of safe pharmacological treatment options for acute rejections, but long-term treatment options remain unsatisfactory. The risk of infection limits the effectiveness of these therapies, and improvements to their efficacy are needed regardless. Specific transplantation tolerance, in which alloreactive T cells are inactivated while the broader immune response is left intact, removing the need for broad immunosuppressant therapies, can be considered as an end-goal for clinical transplantation.

Compared with the overall immunology pipeline, in which there are over 1,900 products, the transplantation pipeline is small, with only about 244 products. However, of the 145 products in the transplantation pipeline with a disclosed molecular target, there are 65 first-in-class products, acting on a total of 63 first-in-class targets. First-in-class products account for 44% of transplantation pipeline products with a disclosed molecular target.

Of the 65 first-in-class pipeline products in development for transplantation and GVHD, those which emerged as being the most promising based on underlying scientific data included cell surface antigens such as CD40 and 47, and chemokines such as CXCR1 and 2. Many of these have yielded promising Preclinical data, although the availability of published clinical data is limited. Nonetheless, many drugs have reached a late stage of development, such as Dompe Farmaceutica’s reparixin, and appear poised to be valuable additions to the relatively stagnant range of treatments for the prevention of transplant rejection, and if successful will be able to drive higher long-term post-transplant survival rates.

The report "Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation" helps to identify innovative pipeline programs across a therapy area, with a focus on indications with high R&D activity and strong innovation, as well as a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming an increasingly vital part of competitive intelligence for all market participants, and increasingly important for companies seeking strategic partnerships or looking to acquire technologies, products or other companies.


  • There is a need for therapies that can achieve graft-specific immunosuppression, without having a general effect on the wider immune system. Which therapies and technologies currently in development are most likely to achieve this?
  • There are 63 distinct first-in-class molecular targets in development for transplantation. Which of these hold the strongest potential in the clinic, and which are closest to reaching the market?
  • How effective are current therapies for these indications, and how have they been able to improve the general prognosis in recent decades?
  • Which molecule types and molecular targets are most prominent across transplantation therapy?
  • Which specific types of transplantation are being most heavily studied across the pharmaceutical pipeline?

Reasons To Buy

  • Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options for transplantation rejection.
  • Identify leading products and key unmet needs within the market.
  • Recognize trends in pipeline innovation by analyzing therapies by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix assessment, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.